Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Cytokinetics' lead asset, Aficamten, shows promise in treating obstructive hypertrophic cardiomyopathy (oHCM) with significant improvements in exercise capacity and fewer adverse events compared ...

Longer-term treatment with aficamten resulted in statistically significant improvements (mean ±SD) in measures of cardiac structure and function including left ventricular mass index (-9.8 g/m2 ...

Shares of Bristol-Myers Squibb Company (NYSE: BMY) edged down 0.6% in premarket trading after announcing its Phase 3 ODYSSEY-HCM trial did not meet its primary endpoints. The study evaluated Camzyos ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...